Selvita S.A. has completed its strategic acquisition of PozLab, a CDMO offering drug product development services and small pilot plant capabilities, including analytical, formulation, and process development competencies, followed by microbiological testing. 
 
PozLab holds a GMP license for the manufacture of medical and investigational products. The company currently employs over 80 subject matter experts and is located in state-of-the-art R&D facilities in Poznan, Poland, which offer approximately 1700 m² of research space.
 
The acquisition expands Selvita’s capabilities in the pharmaceutical research sector. Selvita provides small molecule drug manufacturing services for early-stage clinical trials. This strategic move expands its portfolio with additional valuable competencies.
 
“I would like to extend a very warm welcome to our new colleagues in Poznan. It’s wonderful to have them on board and I am looking forward to all the synergies this new relationship will bring,” said Bogusław Sieczkowski, President of the Management Board of Selvita.